Aptose Biosciences announces the results of its reconvened annual and special meeting of shareholders held on August 22, 2025.
Shareholders voted in favor of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm.
Aptose received an additional advance of US$1.5 million in funding from Hanmi Pharmaceutical Co. Ltd. to support the continued clinical development of tuspetinib.
Appointment of Ernst & Young LLP
Ernst & Young LLP appointed as Aptose's new independent auditor, providing global expertise in the life sciences sector.
Additional Funding from Hanmi Pharmaceutical
Aptose received US$1.5 million advance from Hanmi Pharmaceutical for clinical development of tuspetinib.
Clinical Development Focus
Aptose aims to develop precision medicines in oncology with a focus on hematology using tuspetinib as a lead clinical-stage oral kinase inhibitor.
- The appointment of Ernst & Young LLP enhances Aptose's financial transparency and industry compliance.
- The additional funding from Hanmi Pharmaceutical strengthens Aptose's financial position for further clinical development activities.
The recent results of the shareholders meeting and financial support from Hanmi Pharmaceutical demonstrate Aptose's commitment to advancing precision oncology therapies.